GSK completes BREXAFEMME NDA transfer, to receive $145.5mln milestones and royalties.

• SCYNEXIS completes BREXAFEMME NDA transfer to GSK • GSK to relaunch BREXAFEMME for VVC and rVVC • SCYNEXIS to receive up to $145.5M in annual net sales milestones • Royalties in low to mid single digit range • Net of payments to Merck • GSK to initiate FDA interactions for BREXAFEMME relaunch